Addex Therapeutics Ltd.
http://www.addextherapeutics.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Addex Therapeutics Ltd.
Deal Watch: BI Acquires Nerio For Novel Immune Checkpoint Inhibitor
Featuring deals involving Novartis/Dren, Palvella/Pieris, Eyenovia/Senju, Addex/Johnson & Johnson, Agilent/BioVectra, Meitheal/Nabriva, plus tech transfer agreements and deals in brief.
Addex Gets Creative To Secure Funding And Its Future
Addex Therapeutics’ Tim Dyer has seen the company through 22 years of ups and downs. He has kept the company afloat, and recently did the same by spinning out a new company.
Finance Watch: Obsidian’s $160.5m Financings Comes In A Flurry Of VC Mega-Rounds
Private Company Edition: Three consecutive $100m-plus venture capital rounds include Obsidian’s series C, a $132m series B round for Alterome and Diagonal’s $128m launch. Also, The Medicines Company’s Clive Meanwell reportedly is heading up a well-founded obesity start-up.
Finance Watch: Recent M&A Uptick Gives Biopharma A Needed Boost
Public Company Edition: William Blair analysts note that stock prices are rising due to a Q2 boost in dealmaking after a lull in Q1. Nevertheless, layoffs and portfolio prioritizations are ongoing, including at X4 Pharmaceuticals, but others have raised cash following good news, like Revolution Medicines.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice